

**Anti-Spike RBD Reference Antibody (Casirivimab)
Recombinant Antibody
Catalog # APR10007**

Specification

Anti-Spike RBD Reference Antibody (Casirivimab) - Product Information

Application	FC, E, FTA
Primary Accession	NA
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145.24 KDa

Anti-Spike RBD Reference Antibody (Casirivimab) - Additional Information

Target/Specificity
Spike RBD

Endotoxin
< 0.001EU/ µg,determined by LAL method.

Conjugation
Unconjugated

Expression system
CHO Cell

Format
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.


Anti-Spike RBD Reference Antibody (Casirivimab) - Protein Information

Anti-Spike RBD Reference Antibody (Casirivimab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


Anti-Spike RBD Reference Antibody (Casirivimab) - Images



Anti-Spike RBD Reference Antibody (Casirivimab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-Spike RBD Reference Antibody (Casirivimab) is more than 99.84% ,determined by SEC-HPLC.



Immobilized 2019nCoV RBD His at 2 µg/mL can bind Anti-Spike RBD Reference Antibody (Casirivimab) □EC50=0.006201 µg/mL.